PROMETHAZINE Rx-TO-OTC SWITCH SHOULD NOT BE ALLOWED, FDA ADVISORY PANEL RECOMMENDS; PANEL CONCERNED OVER ASSOCIATION WITH SIDS AND PRESCRIBING ABUSE